LIBREXIA-STROKE: A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient I

Grants and Contracts Details

StatusActive
Effective start/end date7/14/237/14/25

Funding

  • Janssen Research and Development LLC: $10,931.00